Signatera Resources | Natera

PRODUCT SPOTLIGHT

A new way to get earlier, more precise information after cancer treatment

IN THE NEWS

Awarded positive Medicare draft coverage for serial use in Stage II & II CRC



Webinars

 

Signatera Endpoints Webinar

 


Video Vignettes


Natera's Corporate Mission and Vision

About Signatera and Circulating Tumor DNA (ctDNA)

The Signatera Approach

What are Potential Clinical Applications of Signatera?

How can Signatera be Incorporated in Clinical Trials?


Publications

Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. [published online ahead of print May 9, 2019]. JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.0528.
Learn More: View this article

Christensen E, Birkenkamp-Demtröder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma [published online ahead of print May 6, 2019]. J Clin Oncol. 2019. doi:10.1200/JCO.18.02052.
Learn More: View this article

Coombes RC, Page K, Salari R, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence [published online ahead of print April 16, 2019]. Clin Cancer Res. 2019. doi:10.1158/1078-0432.CCR-18-3663.
Learn More: View this article

Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451.
Learn More: View this article

Jamal-Hanjani M, Wilson GA, Horswell S, et al. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann Oncol. 2016;27(5):862-867.
Learn More: View this article

Kirkizlar E, Zimmermann B, Constantin T, et al. Detection of clonal and subclonal copy-number variants in cell-free DNA from patients with breast cancer using a massively multiplexed PCR methodology. Transl Oncol. 2015;8:407-416.
Learn More: View this article

Babiarz JE, Zimmermann BG, Constantin T, et al. Detection of copy number variations in breast cancer samples using single-nucleotide polymorphism-targeted massively multiplexed PCR. Cancer Genet. 2014;207(6):287. 
Learn More: View this article

Posters Presented

Iafolla MAJ, Yang C, Dashner S, et al. Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients treated with single-agent pembrolizumab. Poster presented at: American Society of Clinical Oncology Annual Meeting; June 1, 2019. Chicago, IL. Abstract 2542.
Learn More: View this poster

Coombes RC, Armstrong A, Ahmed S, et al. Early detection of residual breast cancer through a robust, scalable and personalized analysis of circulating tumor DNA (ctDNA) antedates overt metastatic recurrence. Poster presented at: San Antonio Breast Cancer Symposium; December 7, 2018. San Antonio, TX. Abstract 1266.
Learn More: View this poster

Magbanua MJM, Brown-Swigart L, Hirst GL, et al. Personalized serial circulating tumor DNA (ctDNA) analysis in high-risk early stage breast cancer patients to monitor and predict response to neoadjuvant therapy and outcome in the I-SPY 2 trial. Poster presented at: San Antonio Breast Cancer Symposium; December 5, 2018. San Antonio, TX. Abstract 1259.
Learn More: View this poster

Reinert T, Henriksen TV, Rasmussen MH, et al. Serial Circulating Tumor DNA Analysis for Detection of Residual Disease, Assessment of Adjuvant Therapy Efficacy and for Early Recurrence Detection in Colorectal Cancer. Poster presented at: European Society for Medical Oncology Annual Congress; October 21, 2018; Munich, Germany. Abstract 456PD. 
Learn More: View this poster

Birkenkamp-Demtröder K, Christensen E, Sethi H, et al. Sequencing of Plasma cfDNA from Patients with Locally Advanced Bladder Cancer for Surveillance and Therapeutic Efficacy Monitoring. Poster presented at: European Society for Medical Oncology Annual Congress; October 20, 2018; Munich, Germany. Abstract 86P.
Learn More: View this poster

Birkenkamp-Demtröder K, Christensen E, Sharma S, et al. Sequencing of plasma cfDNA from patients with locally advanced bladder cancer for surveillance and therapeutic efficacy monitoring. Poster presented at: American Association for Cancer Research Annual Meeting; April 17, 2018; Chicago, IL. Abstract 3653.
Learn More: View this poster

Reinert T, Henriksen TV, Rasmussen MH, et al. Personalized circulating tumor DNA analysis to monitor colorectal cancer. Poster presented at: American Association for Cancer Research Annual Meeting; April 17, 2018; Chicago, IL. Abstract 1590.
Learn More: View this poster

Sethi H, Salari R, Navarro S, et al. Analytical validation of the Signatera™ RUO assay, a highly sensitive patient-specific multiplex PCR NGS-based noninvasive cancer recurrence detection and therapy monitoring assay. Poster presented at: American Association for Cancer Research (AACR) Annual Meeting; April 17, 2018; Chicago, IL. Abstract 4542. 
Learn More: View this poster

Correa A, Connolly DC, Balcioglu M, et al. Presence of Circulating Tumor DNA in Surgically Resected Renal Cell Carcinoma is Associated with Advanced Disease and Poor Patient Prognosis. Poster presented at: European Society for Medical Oncology (ESMO) Congress; September 30, 2019. Barcelona, Spain. Abstract #110P.
Learn More: View this poster

Jacobs S, Sethi H, Kolveska T, et al. Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer After Adjuvant Chemotherapy. Poster presented at: European Society for Medical Oncology (ESMO) Congress; September 30, 2019. Barcelona, Spain. Abstract #166P.
Learn More: View this poster


Questions about Signatera? Contact us.